Cryoballoon catheter Launched In India
--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

Cryoballoon catheter Launched In India: Medtronic

Arctic Front™ Cardiac Cryoablation Catheter System, the 1st and only cryoballoon catheter authorized by the CDSCO for treating atrial fibrillation (AF) in India, has launched India Medtronic.

Dr. Balbir Singh, chairman of Cardiology, Pan Max Hospital Saket, Delhi, successfully conducted the 1st Arctic Front Cardiac Cryoablation Catheter System surgery in India. One of the therapeutic modalities for AF is cryoballoon catheter ablation, a minimally invasive procedure.

As AF is a progressive disease, patients may undergo more frequent and lengthier episodes over time. Cryoballoon ablation is a reliable and efficient treatment for atrial fibrillation that can be used before or after medication therapy. By treating patients with the most state-of-the-art, clinically relevant technology, they can better manage their AF, thereby developing their quality of life.

The prominent role of the Medtronic cryoballoon catheter is to isolate the pulmonary vein. This unique method has been utilized to treat over 1,000,000 patients in over 80 nations, with robust safety and efficacy data released in over 1200 peer-reviewed articles.

Madan Krishnan, vice president, and managing director of Medtronic India, stated that cryoballoon ablation is a minimally invasive method with similar safety and performance to standard radiofrequency therapy, however

, with the advantage of greater treatment potency. In association with the world’s leading clinicians, researchers, and experts, Medtronic provides the most comprehensive array of ingenious medical technology to treat cardiovascular disease and cardiac arrhythmias interventionally and surgically.

Medtronic received expanded FDA approval in June 2021 for the Arctic Front™ Family of Cardiac Cryoablation Catheters for treating recurrent symptomatic paroxysmal atrial fibrillation (episodes lasting less than 7 continuous days) as an alternative to antiarrhythmic drug therapy as an initial rhythm control approach. This unique indication expansion should enable doctors to treat AF patients earlier in the disease progression phase, potentially improving therapeutic efficacy.


Also Read:

Check out Biotecnika App for more recent Updates, News, and Job vacancies.

Keywords: Cryoballoon catheter Launched In India: Medtronic